Loading...
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1
LMB-100 is a recombinant immunotoxin being developed for cancer treatment that is composed of a Fab that binds to mesothelin and a portion of Pseudomonas exotoxin A. LMB-100 is in clinical trials for the treatment of mesothelioma and pancreatic cancer. To determine if check point modulating antibodi...
Na minha lista:
| Udgivet i: | Cell Immunol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310483/ https://ncbi.nlm.nih.gov/pubmed/30213644 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cellimm.2018.08.016 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|